Albert Schatz: from two cultures to a tuberculosis trial
Albert Schatz dated his recognition of streptomycin to October 19, 1943, while he was a graduate student in Selman Waksman's laboratory at Rutgers. The discovery joined two ambitions: finding an antibiotic active against gram-negative bacteria and finding one active against the tubercle bacillus. In a recollection published in 1993, he placed the decisive moment at about 2 p.m. That precise hour comes from his memory 50 years later. The preparation patent, filed in 1945, supplies a different kind of evidence: a named substance, a reproducible production process and two inventors, Waksman and Schatz.
The organisms came from more than one place. Albert Schatz recalled isolating one productive strain of Streptomyces griseus from heavily manured soil. He designated it 18-16: the sixteenth actinomycete isolated from the eighteenth soil sample. Another strain, D-1, came from a culture plate supplied by fellow graduate student Doris Jones, who was investigating microorganisms from chickens' throats. Schatz identified the bird as healthy. In his description, the soil isolate and the poultry-laboratory isolate both produced the same antibiotic. The result depended on testing what the cultures produced, rather than simply finding a microorganism with an unfamiliar name.
The American Chemical Society's later history places this work within Waksman's established program of screening soil microorganisms for antibacterial activity. It also records that Albert Schatz appeared first on the initial discovery publication and that his 1945 doctoral thesis concerned streptomycin. Laboratory authorship and patent inventorship left different records of the work. U.S. Patent 2,449,866, titled Streptomycin and Process of Preparation, names Waksman and Schatz and assigns the invention to the Rutgers Research and Endowment Foundation. Its application date is February 9, 1945; the grant followed on September 21, 1948. Neither date is the date of the original isolation.
The patent calls the producing organism Actinomyces griseus. Its central distinction is between growing that organism and recovering the active substance from its broth. The inventors described a water-soluble material that inhibited numerous gram-positive and gram-negative bacteria. They compared its antibacterial activity with streptothricin, an earlier product of the Rutgers investigations. Their measurements used a biological unit defined by inhibition of a standard strain of Escherichia coli. Potency was therefore tied to a specified bacterial test, rather than to the volume or appearance of a flask's contents.
Cultivation was itself adjustable. The patent describes stationary surface cultures and submerged cultures supplied with agitation and air. Its stated production periods were approximately six to twelve days for stationary growth and two to four days for submerged aerobic growth. Meat extract or corn steep liquor supplied a growth-promoting component of the medium. After cultivation, filtration or centrifugation separated the microbial growth from the broth. Activated charcoal collected the antibiotic, which was then released with acidified alcohol and recovered in solution. These operations turned antibacterial activity in a culture into material that could be isolated and handled separately.
Albert Schatz also remembered the labor needed before industrial supplies existed. For early Mayo Clinic investigations, he used numerous one-liter flasks holding 250 milliliters of broth and ran stills to recover solvents. He described sleeping on a laboratory bench while production continued. These are recollections of his working routine, rather than measurements from the patent. Together, the two records connect the physical work of preparing experimental batches with the formal process later claimed by the inventors. Growing a productive culture and supplying enough antibiotic for further experiments were separate practical achievements.
Clinical testing supplied another essential distinction. The Medical Research Council's report of October 30, 1948, compared 55 patients given streptomycin plus bed rest with 52 assigned to bed rest without streptomycin. The patients had acute progressive tuberculosis affecting both lungs and were assigned to the groups by random selection. After six months, four patients in the streptomycin group had died, compared with fourteen controls. Chest radiographs showed considerable improvement in 28 treated patients and four controls. Those results concerned a defined group and observation period, rather than an assurance that every form of tuberculosis would respond equally.
The same investigation recorded limitations. Among 41 treated patients with suitable bacteriological data, 35 yielded strains with resistance more than ten times that of the standard comparison organism. The investigators associated higher resistance with poorer outcomes while also considering how ill patients had been initially. The clinical gains were substantial, but continued bacterial resistance complicated treatment. The path from Albert Schatz and his culture plates to tuberculosis therapy included controlled comparisons and laboratory follow-up, with setbacks visible alongside the gains.
Credit and income became the subject of litigation. Rutgers' archival description records that Albert Schatz sued Waksman and the Foundation for recognition and royalties; the settlement awarded him co-discoverer status, three percent of royalties and $125,000. The Chemical Society dates the settlement to December 1950 and records Waksman's Nobel Prize in 1952. Albert Schatz's name on the patent and his recognition in the settlement mark two distinct forms of acknowledgment.
- Selman A. Waksman and Albert Schatz, U.S. Patent 2,449,866, Streptomycin and Process of Preparation, 1948 — patents.google.com
- Albert Schatz, The True Story of the Discovery of Streptomycin, Actinomycetes 4(2), 1993: later personal recollection — www.albertschatzphd.com
- Medical Research Council, Streptomycin Treatment of Pulmonary Tuberculosis, British Medical Journal, October 30, 1948, pp. 769–782 — pmc.ncbi.nlm.nih.gov
- Rutgers University Archives, Selman A. Waksman Papers: Waksman v. Schatz Case, archival description — archives.libraries.rutgers.edu
- American Chemical Society, Selman Waksman and Antibiotics: National Historic Chemical Landmark history — www.acs.org